Get the Stockscreener App
1,075.47
2.61%
-28.87
After Hours:
1074.59
-0.88
-0.08%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,075.47, with a volume of 2.73M.
It is down -2.61% in the last 24 hours and up +31.14% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,104.34
Open:
$1096.72
24h Volume:
2.73M
Relative Volume:
0.73
Market Cap:
$1.02T
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
53.19
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+1.49%
1M Performance:
+31.14%
6M Performance:
+49.50%
1Y Performance:
+36.45%
1-Day Range:
$1,067.69
$1,099.05
1-Week Range:
$1,049.38
$1,111.99
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,075.47 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.92 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.70 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.40 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.83 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly’s Swiss Trading Update: Examining the Metrics - Meyka
Eli Lilly to Set up Manufacturing Base for Mounjaro in Korea in Partnership with SK Inc. - Businesskorea
Eli Lilly News Today, Nov 30: Significant Volume Surge Signals Market Interest - Meyka
Jim Cramer Says Eli Lilly “May Have the Greatest Drug Franchise of All Time” With GLP-1 and Diabetes Medication - Insider Monkey
Jim Cramer Says Eli Lilly "May Have the Greatest Drug Franchise of All Time" With GLP-1 and Diabetes Medication - Finviz
Is Eli Lilly a Millionaire Maker? - The Motley Fool
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge - ts2.tech
Eli Lilly, Strategy, Applied Materials, Rocket Lab, and QuantumScape: Insider Moves Unveiled - TipRanks
Does Eli Lilly’s Rally Signal a Better Value After Its Weight-Loss Drug Breakthrough? - simplywall.st
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors - ts2.tech
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MSN
Why Eli Lilly's 'market-cap explosion' might be 'misplaced' - Yahoo Finance
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides - MSN
Eli Lilly Stock (LLY) Rose 30% in November - TipRanks
Eli Lilly (LLY) Stock Today, November 28, 2025: Post–$1 Trillion Milestone, Is the Rally Catching Its Breath? - ts2.tech
Eli Lilly Unusual Options ActivityEli Lilly (NYSE:LLY) - Benzinga
Micron, Eli Lilly among market cap stock movers on Friday By Investing.com - Investing.com Nigeria
Micron, Eli Lilly among market cap stock movers on Friday - Investing.com
Finance Watch: Lilly Toes The $1 Trillion Valuation Line - Citeline News & Insights
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Eli Lilly divulges new RXFP1 agonists - BioWorld MedTech
Peptron falls after-hours as Eli Lilly extends tech evaluationCHOSUNBIZ - Chosunbiz
Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider - GlobeNewswire Inc.
Key facts: Eli Lilly co-develops ELUNATE®; Endowment sells 162,693 shares - TradingView
Eli Lilly and Company Stock (LLY) Opinions on $1 Trillion Market Cap Milestone - Quiver Quantitative
Eli Lilly’s (LLY) Endowment Becomes the Largest in the U.S. with $100 Billion of Assets - TipRanks
Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus - ts2.tech
Will Eli Lilly and Company stock outperform growth indexesJuly 2025 Levels & Risk Controlled Swing Trade Alerts - BỘ NỘI VỤ
Eli Lilly Becomes First Healthcare Company Globally to Cross $1 Trillion Market Cap, Driven by Explosive GLP-1 Growth - eHealth Magazine
Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green! - Barchart.com
How Eli Lilly's weight-loss drugs propelled it to a $1 trillion valuation - fastcompany.co.za
Eli Lilly joins a very exclusive club - MarketScreener
JAMIE CARR: Pill popping puts Eli Lilly on a high - Business Day
Eli Lilly Becomes First Pharmaceutical To Hit $1 Trillion Valuation - InkFreeNews.com
Why Eli Lilly (LLY) Hit $1 Trillion as Obesity Drug Momentum Ignites Investor Optimism - Yahoo Finance
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly and Company
School board OKs tax abatement deal for Eli Lilly's $6.5B Houston-area plant - The Business Journals
Eli Lilly: $1 Trillion Built On One Drug Segment (LLY) - Seeking Alpha
Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout - BioWorld MedTech
JPMorgan Analyst Pounds the Table on Eli Lilly Stock (LLY) - TipRanks
Eli Lilly Crosses the $1 Trillion Line While the World Obsesses Over AI - Quasa.io
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026 - Finviz
Lilly rolling out direct-to-employer obesity drug coverage - Inside INdiana Business
Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz - ts2.tech
Stock Split Watch: Is Eli Lilly Next? - AOL.com
Implications of Medicare Price Changes on Eli Lilly (LLY) - GuruFocus
Eli Lilly (LLY) Is Up 7.8% After Surpassing $1 Trillion Valuation on Obesity Drug Demand – Has The Bull Case Changed? - simplywall.st
BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood - Yahoo Finance
Jim Cramer Discusses Eli Lilly (LLY) Touching the Trillion Dollar Market Value - MSN
JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating - Yahoo Finance
Major Shareholder Cashes In on Eli Lilly Stock! - TipRanks
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):